|
Have Questions?
Global Headquarters
Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157
North America
Tel: 1-617-573-9450
Fax: 1-617-573-9542
Japan
Tel: +81 (0)80-1164-4754
Request a Demo
What our customers are saying
When I think of the future, I think of EvaluatePharma
Senior Director,
Global pharmaceutical company
EP Vantage Shifting CAR-Ts Into a Higher Gear
EP Vantage Shifting CAR-Ts Into a Higher Gear
Chimeric antigen receptor T cell (CAR-T) therapy has indisputably become one of the industry’s hottest topics and the next 18 months could see the first CAR-T drugs filed for US approval. But behind the excitement for all things CAR-T lie a number of obstacles in their path to approval.
In its second deep-dive into the CAR-T space EP Vantage explores how much of an advantage it will be for the first company to achieve approval in a market that has never been tested and the ability to charge premium pricing can only be guessed at. |
This comprehensive report analyses:
- The complexity and expense of manufacturing
- The poor durability of many current CAR constructs
- The growing ways by which tumour cells can become resistant to CAR-T therapy
- The fear of severe toxicities
- The cost and reimbursement questions surrounding CAR-T treatments
Press Release
Confirm your details on form below to download this report
|